

OPEN

A novel phytocannabinoid isolated from *Cannabis sativa* L. with an *in vivo* cannabimimetic activity higher than Δ^9 -tetrahydrocannabinol: Δ^9 -Tetrahydrocannabiphorol

Cinzia Citti^{1,2,3,6}, Pasquale Linciano^{3,6}, Fabiana Russo³, Livio Luongo⁴, Monica Iannotta⁴, Sabatino Maione⁴, Aldo Laganà^{2,5}, Anna Laura Capriotti⁵, Flavio Forni³, Maria Angela Vandelli³, Giuseppe Gigli² & Giuseppe Cannazza^{2,3*}

(-)-*Trans*- Δ^9 -tetrahydrocannabinol (Δ^9 -THC) is the main compound responsible for the intoxicant activity of *Cannabis sativa* L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ^9 -THC with a longer side chain have shown cannabimimetic properties far higher than Δ^9 -THC itself. In the attempt to define the phytocannabinoids profile that characterizes a medicinal cannabis variety, a new phytocannabinoid with the same structure of Δ^9 -THC but with a seven-term alkyl side chain was identified. The natural compound was isolated and fully characterized and its stereochemical configuration was assigned by match with the same compound obtained by a stereoselective synthesis. This new phytocannabinoid has been called (-)-*trans*- Δ^9 -tetrahydrocannabiphorol (Δ^9 -THCP). Along with Δ^9 -THCP, the corresponding cannabidiol (CBD) homolog with seven-term side alkyl chain (CBDP) was also isolated and unambiguously identified by match with its synthetic counterpart. The binding activity of Δ^9 -THCP against human CB₁ receptor *in vitro* ($K_i = 1.2$ nM) resulted similar to that of CP55940 ($K_i = 0.9$ nM), a potent full CB₁ agonist. In the cannabinoid tetrad pharmacological test, Δ^9 -THCP induced hypomotility, analgesia, catalepsy and decreased rectal temperature indicating a THC-like cannabimimetic activity. The presence of this new phytocannabinoid could account for the pharmacological properties of some cannabis varieties difficult to explain by the presence of the sole Δ^9 -THC.

Cannabis sativa has always been a controversial plant as it can be considered as a lifesaver for several pathologies including glaucoma¹ and epilepsy², an invaluable source of nutrients³, an environmentally friendly raw material for manufacturing⁴ and textiles⁵, but it is also the most widely spread illicit drug in the world, especially among young adults⁶.

Its peculiarity is its ability to produce a class of organic molecules called phytocannabinoids, which derive from an enzymatic reaction between a resorcinol and an isoprenoid group. The modularity of these two parts is the key for the extreme variability of the resulting product that has led to almost 150 different known phytocannabinoids⁷. The precursors for the most commonly naturally occurring phytocannabinoids are olivetolic acid and geranyl pyrophosphate, which take part to a condensation reaction leading to the formation of cannabigerolic acid (CBGA). CBGA can be then converted into either tetrahydrocannabinolic acid (THCA) or cannabidiolic

¹Meditekology spin-off company of the National Council of Research (CNR), Via Arnesano, 73100, Lecce, Italy.

²Institute of Nanotechnology of the National Council of Research (CNR NANOTEC), Via Monteroni, 73100, Lecce, Italy. ³Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125, Modena, Italy.

⁴Department of Experimental Medicine, Division of Pharmacology, Università della Campania "L. Vanvitelli", Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy. ⁵Department of Chemistry, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy. ⁶These authors contributed equally: Cinzia Citti and Pasquale Linciano.

*email: giuseppe.cannazza@unimore.it

acid (CBDA) or cannabichromenic acid (CBCA) by the action of a specific cyclase enzyme⁷. All phytocannabinoids are biosynthesized in the carboxylated form, which can be converted into the corresponding decarboxylated (or neutral) form by heat⁸. The best known neutral cannabinoids are undoubtedly Δ^9 -tetrahydrocannabinol (Δ^9 -THC) and cannabidiol (CBD), the former being responsible for the intoxicant properties of the cannabis plant, and the latter being active as antioxidant, anti-inflammatory, anti-convulsant, but also as antagonist of THC negative effects⁹.

All these cannabinoids are characterized by the presence of an alkyl side chain on the resorcinyl moiety made of five carbon atoms. However, other phytocannabinoids with a different number of carbon atoms on the side chain are known and they have been called varinoids (with three carbon atoms), such as cannabidivarin (CBDV) and Δ^9 -tetrahydrocannabivarin (Δ^9 -THCV), and orcinoids (with one carbon atom), such as cannabidiolcol (CBD-C₁) and tetrahydrocannabiorcol (THC-C₁)⁷. Both series are biosynthesized in the plant as the specific ketide synthases have been identified¹⁰.

Our research group has recently reported the presence of a butyl phytocannabinoid series with a four-term alkyl chain, in particular cannabidibutol (CBDB) and Δ^9 -tetrahydrocannabutol (Δ^9 -THCB), in CBD samples derived from hemp and in a medicinal cannabis variety^{11,12}. Since no evidence has been provided for the presence of plant enzymes responsible for the biosynthesis of these butyl phytocannabinoids, it has been suggested that they might derive from microbial ω -oxidation and decarboxylation of their corresponding five-term homologs¹³.

The length of the alkyl side chain has indeed proved to be the key parameter, the pharmacophore, for the biological activity exerted by Δ^9 -THC on the human cannabinoid receptor CB₁ as evidenced by structure-activity relationship (SAR) studies collected by Bow and Rimondi¹⁴. In particular, a minimum of three carbons is necessary to bind the receptor, then the highest activity has been registered with an eight-carbon side chain to finally decrease with a higher number of carbon atoms¹⁴. Δ^8 -THC homologs with more than five carbon atoms on the side chain have been synthetically produced and tested in order to have molecules several times more potent than Δ^9 -THC^{15,16}.

To the best of our knowledge, a phytocannabinoid with a linear alkyl side chain containing more than five carbon atoms has never been reported as naturally occurring. However, our research group disclosed for the first time the presence of seven-term homologs of CBD and Δ^9 -THC in a medicinal cannabis variety, the Italian FM2, provided by the Military Chemical Pharmaceutical Institute in Florence. The two new phytocannabinoids were isolated and fully characterized and their absolute configuration was confirmed by a stereoselective synthesis. According to the International Non-proprietary Name (INN), we suggested for these CBD and THC analogues the name “cannabidiphorol” (CBDP) and “tetrahydrocannabiphorol” (THCP), respectively. The suffix “-phorol” comes from “sphaerophorol”, common name for 5-heptyl-benzen-1,3-diol, which constitutes the resorcinyl moiety of these two new phytocannabinoids.

A number of clinical trials^{17–19} and a growing body of literature provide real evidence of the pharmacological potential of cannabis and cannabinoids on a wide range of disorders from sleep to anxiety, multiple sclerosis, autism and neuropathic pain^{20–23}. In particular, being the most potent psychotropic cannabinoid, Δ^9 -THC is the main focus of such studies. In light of the above and of the results of the SAR studies^{14–16}, we expected that THCP is endowed of an even higher binding affinity for CB₁ receptor and a greater cannabimimetic activity than THC itself. In order to investigate these pharmacological aspects of THCP, its binding affinity for CB₁ receptor was tested by a radioligand *in vitro* assay and its cannabimimetic activity was assessed by the tetrad behavioral tests in mice.

Results

Identification of cannabidiphorol (CBDP) and Δ^9 -tetrahydrocannabiphorol (Δ^9 -THCP) by liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS). The FM2 ethanolic extract was analyzed by an analytical method recently developed for the cannabinoid profiling of this medicinal cannabis variety^{12,24}. As the native extract contains mainly the carboxylated forms of phytocannabinoids as a consequence of a cold extraction²⁵, part of the plant material was heated to achieve decarboxylation where the predominant forms are neutral phytocannabinoids. The advanced analytical platform of ultra-high performance liquid chromatography coupled to high resolution Orbitrap mass spectrometry was employed to analyze the FM2 extracts and study the fragmentation spectra of the analytes under investigation. The precursor ions of the neutral derivatives cannabidiphorol (CBDP) and Δ^9 -tetrahydrocannabiphorol (Δ^9 -THCP), 341.2486 for the [M-H]⁻ and 343.2632 for the [M + H]⁺, showed an elution time of 19.4 min for CBDP and 21.3 min for Δ^9 -THCP (Fig. 1a). Their identification was confirmed by the injection of a mixture (5 ng/mL) of the two chemically synthesized CBDP and Δ^9 -THCP (Fig. 1b) as it will be described later. As for their carboxylated counterpart, the precursor ions of the neutral forms CBDP and Δ^9 -THCP break in the same way in ESI+ mode, but they show a different fragmentation pattern in ESI- mode. Whilst Δ^9 -THCP shows only the precursor ion [M-H]⁻ (Fig. 1d), CBDP molecule generates the fragments at *m/z* 273.1858 corresponding to a retro Diels-Alder reaction, and 207.1381 corresponding to the resorcinyl moiety after the break of the bond with the terpenoid group (Fig. 1c). It is noteworthy that for both molecules, CBDP and Δ^9 -THCP, each fragment in both ionization modes differ exactly by an ethylene unit (CH₂)₂ from the corresponding five-termed homologs CBD and THC. Moreover, the longer elution time corroborates the hypothesis of the seven-termed phytocannabinoids considering the higher lipophilicity of the latter.

Isolation and characterization of natural CBDP and Δ^9 -THCP. In order to selectively obtain a cannabinoid-rich fraction of FM2, *n*-hexane was used to extract the raw material instead of ethanol, which carries other contaminants such as flavonoids and chlorophylls along with cannabinoids²⁶. An additional dewaxing step at -20 °C for 48 h and removal of the precipitated wax was necessary to obtain a pure cannabinoids extract. Semi-preparative liquid chromatography with a C₁₈ stationary phase allowed for the separation of 80 fractions,




Figure 1. UHPLC-HRMS identification of (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP. Extracted ion chromatograms (EIC) of CBDP and Δ^9 -THCP from a standard mixture at 25 and 10 ng/mL respectively (a) and from the native (red plot) and decarboxylated (black plot) FM2 (b). (c,d) Comparison of the high-resolution fragmentation spectra of synthetic and natural CBDP and Δ^9 -THCP in both positive (ESI+) and negative (ESI-) mode.

which were analyzed by LC-HRMS with the previously described method. In this way, the fractions containing predominantly cannabidiophoric acid (CBDPA) and tetrahydrocannabipgorolic acid (THCPA) were separately subject to heating at 120 °C for 2 h in order to obtain their corresponding neutral counterparts CBDP and Δ^9 -THCP as clear oils with a >95% purity. The material obtained was sufficient for a full characterization by ¹H and ¹³C NMR, circular dichroism (CD) and UV absorption.

Stereoselective synthesis of CBDP and Δ^9 -THCP. (-)-*trans*-Cannabidiophorol ((-)-*trans*-CBDP) and (-)-*trans*- Δ^9 -tetrahydrocannabiphorol ((-)-*trans*- Δ^9 -THCP) were stereoselectively synthesized as previously reported for the synthesis of (-)-*trans*-CBDDB and (-)-*trans*- Δ^9 -THCB homologs^{11,12,24}. Accordingly, (-)-*trans*-CBDP was prepared by condensation of 5-heptylbenzene-1,3-diol with (1*S*,4*R*)-1-methyl-4-(prop-1-en-2-yl)cycloex-2-enol, using *p*TSA as catalyst, for 90 min. Longer reaction time did not improve the yield of (-)-*trans*-CBDP because cyclization of (-)-*trans*-CBDP to (-)-*trans*- Δ^9 -THCP and then to (-)-*trans*- Δ^8 -THCP occurred. 5-heptylbenzene-1,3-diol was synthesized first as reported in the Supporting Information (Supplementary Fig. SI-1). The conversion of (-)-*trans*-CBDP to (-)-*trans*- Δ^9 -THCP using diverse Lewis' acids, as already reported in the literature for the synthesis of the homolog Δ^9 -THC²⁷⁻²⁹, led to a complex mixture of isomers which resulted in an arduous and low-yield isolation of (-)-*trans*- Δ^9 -THCP by standard chromatographic techniques. Therefore, for the synthesis of (-)-*trans*- Δ^9 -THCP, its regioisomer (-)-*trans*- Δ^8 -THCP was synthesized first by condensation of 5-heptylbenzene-1,3-diol with (1*S*,4*R*)-1-methyl-4-(prop-1-en-2-yl)cycloex-2-enol, as described above, but the reaction was left stirring for 48 hours. Alternatively, (-)-*trans*-CBDP could be also quantitatively converted to (-)-*trans*- Δ^8 -THCP in the same conditions. Hydrochlorination of the Δ^8 double bond of (-)-*trans*- Δ^8 -THCP, using ZnCl₂ as catalyst, allowed to obtain (-)-*trans*-HCl-THCP, which was successively converted to (-)-*trans*- Δ^9 -THCP in 87% yield by selective elimination on position 2 of the terpene moiety using potassium *t*-amylate as base (Fig. 2a).

The chemical identification of synthetic (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP, and their unambiguous ¹H and ¹³C assignments were achieved by NMR spectroscopy (Supplementary Table SI-1,2 and Supplementary Fig. SI-2,3). Since (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP differ from the respective homologs (CBD, CBDDB, CBDV, Δ^9 -THC, Δ^9 -THCB and Δ^9 -THCV) solely for the length of the alkyl chain on the resorcinyl moiety, no significant differences in the proton chemical shifts of the terpene and aromatic moieties were observed for CBD and Δ^9 -THC homologs. The perfect match in the chemical shift of the terpene and aromatic moieties between the synthesized (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP and the respective homologues^{11,24,30}, combined with the mass spectra and fragmentation pattern, allowed us to unambiguously confirm the chemical structures of the two new synthetic cannabinoids. The *trans* (1*R*,6*R*) configuration at the terpene moiety was confirmed by optical rotatory power. The new cannabinoids (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP showed an $[\alpha]_D^{20}$ of -145° and -166°, respectively, in chloroform. The $[\alpha]_D^{20}$ values were in line with those of the homologs^{11,31}, suggesting a




Figure 2. Synthesis and spectroscopic characterization of (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP. **(a)** Reagents and conditions: **(a)** 5-heptylbenzene-1,3-diol (1.1 eq.), *p*TSA (0.1 eq.), CH_2Cl_2 , r.t., 90 min.; **(b)** 5-heptylbenzene-1,3-diol (1.1 eq.), *p*TSA (0.1 eq.), DCM, r.t., 48 h; **(c)** *p*TSA (0.1 eq.), DCM, r.t., 48 h; **(d)** ZnCl_2 (0.5 eq.), 4N HCl in dioxane (1 mL per 100 mg of Δ^8 -THCP), dry DCM, argon, 0°C to r.t., 2 h. **(e)** 1.75 M potassium *t*-amylate in toluene (2.5 eq.), dry toluene, argon, -15°C, 1 h. **(b–g)** Superimposition of ^1H , ^{13}C NMR and CD spectra for natural (red line) and synthesized (blue line) (-)-*trans*-CBDP **(b–d)** and (-)-*trans*- Δ^9 -THCP **(e–g)**.

(1*R*,6*R*) configuration for both CBDP and Δ^9 -THCP. A perfect superimposition between the ^1H (Fig. 2b,e) and ^{13}C NMR spectra (Fig. 2c,f) and the circular dichroism absorption (Fig. 2d,g) of both synthetic and extracted (-)-*trans*-CBDP and (-)-*trans*- Δ^9 -THCP was observed, confirming the identity of the two new cannabinoids identified in the FM2 cannabis variety.

Binding affinity at human CB_1 and CB_2 receptors. The binding affinity of (-)-*trans*- Δ^9 -THCP against purified human CB_1 and CB_2 receptors was determined in a radioligand binding assay, using [^3H]CP55940 or [^3H]WIN 55212-2 as reference compounds, and dose-response curves were determined (Fig. 3a,b). (-)-*trans*- Δ^9 -THCP binds with high affinity to both human CB_1 and CB_2 receptors with a K_i of 1.2 and 6.2 nM, respectively. (-)-*trans*- Δ^9 -THCP resulted 33-times more active than (-)-*trans*- Δ^9 -THC ($K_i = 40$ nM), 63-times




Figure 3. *In vitro* activity and docking calculation of Δ^9 -THCP. **(a)** Binding affinity (K_i) of the four homologues of Δ^9 -THC against human CB_1 and CB_2 receptors. **(b)** Dose-response studies of Δ^9 -THCP against hCB_1 (in blue) and hCB_2 (in grey). All experiments were performed in duplicate and error bars denote s.e.m. of measurements. **(c)** Docking pose of (-)-*trans*- Δ^9 -THCP (blue sticks), in complex with hCB_1 receptor (PDB ID: 5XRA, orange cartoon). Key amino acidic residues are reported in orange sticks. H-bonds are reported in yellow dotted lines. Heteroatoms are color-coded: oxygen in red, nitrogen in blue and sulphur in yellow. **(d)** Binding pocket of hCB_1 receptor, highlighting the positioning of the heptyl chain within the long hydrophobic channel of the receptor (yellow dashed line). The side hydrophobic pocket is bordered in magenta. Panels **c** and **d** were built using Maestro 10.3 of the Schrödinger Suite.

more active than (-)-*trans*- Δ^9 -THCV ($K_i = 75.4$ nM) and 13-times more active than the newly discovered (-)-*trans*- Δ^9 -THCB ($K_i = 15$ nM) against CB_1 receptor^{12,14}. Moreover, the new identified (-)-*trans*- Δ^9 -THCP resulted about 5- to 10-times more active against CB_2 receptor ($K_i = 6.2$ nM), in contrast with (-)-*trans*- Δ^9 -THC, (-)-*trans*- Δ^9 -THCB and (-)-*trans*- Δ^9 -THCV, which instead showed a comparable binding affinity with a K_i ranging from 36 to 63 nM (Fig. 3a)^{12,14}.

The highest activity of (-)-*trans*- Δ^9 -THCP, compared to the shorter homologues, was investigated by docking calculation. The X-ray structure of the active conformation of hCB_1 receptor in complex with the agonist AM11542 (PDB ID: 5XRA) was used as reference for docking since marked structural changes in the orthosteric ligand-binding site are observed in comparison with the conformation of the receptor bound to an antagonist^{32,33}. AM11542 is a synthetic Δ^8 cannabinoid with high affinity against hCB_1 receptor ($K_i = 0.11$ nM) possessing a 7'-bromo-1',1'-dimethyl-heptyl aliphatic chain at C3 of the resorcinyl moiety. As expected, due to the close chemical similarity, the predicted binding mode of (-)-*trans*- Δ^9 -THCP (Fig. 3c) reflected that of AM11542 in the CB_1 crystal structure (Fig. SI-6a,b)¹⁸. (-)-*trans*- Δ^9 -THCP bound in the active conformation of CB_1 in an L-shaped pose. The tetrahydro-6*H*-benzo[*c*]chromene ring system is located within the main hydrophobic pocket delimited by Phe174, Phe177, Phe189, Lys193, Pro269, Phe170, and Phe268. In particular, the aromatic ring of the resorcinyl moiety is involved in two edge-to-face π - π interactions with Phe170 and Phe268, whereas the phenolic hydroxyl group at C1 is engaged in a H-bond with Ser383 (Fig. 3c). Interestingly, the heptyl chain at C3




Figure 4. Dose-dependent effects of Δ^9 -THCP administration (2.5, 5, or 10 mg/kg, i.p.) on the tetrad phenotypes in mice in comparison to vehicle. **(a)** Time schedule of the tetrad tests in minutes from Δ^9 -THCP or vehicle administration. **(b,c)** Locomotion decrease induced by Δ^9 -THCP administration in the open field test. **(d)** Decrease of body temperature after Δ^9 -THCP administration; the values are expressed as the difference between the basal temperature (i.e., taken before Δ^9 -THCP or vehicle administration) and the temperature measured after Δ^9 -THCP or vehicle administration. **(e)** Increase in the latency for moving from the catalepsy bar after Δ^9 -THCP administration. **(f)** Increase in the latency after the first sign of pain shown by the mouse in the hot plate test following Δ^9 -THCP administration. Data are represented as mean \pm SEM of 5 mice per group. * indicate significant differences compared to 0 (vehicle injection), respectively. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus Δ^9 -THCP 0 mg/kg (vehicle). The Kruskal-Wallis test followed by Dunn's post hoc tests were performed for statistical analysis.

extended into a long hydrophobic tunnel formed by Leu193, Val196, Tyr275, Iso271, Leu276, Trp279, Leu359, Phe379, and Met363 (Fig. 3c,d). Because the predicted pose of the tricyclic tetrahydrocannabinol ring system is conserved among the four THC homologs (Supplementary Fig. SI-7a–c), the length of the alkyl chain at C3 of the resorciny moiety could account for the different binding affinity observed among the four cannabinoids. (-)-*trans*- Δ^9 -THCP (Fig. 3c) and (-)-*trans*- Δ^9 -THC (Supplementary Fig. SI-7a) share the same positioning of the alkyl 'tail' within the hydrophobic channel^{12,33,34}. However, the long heptyl chain of Δ^9 -THCP is able to extend into the tunnel along its entire length, maximizing the hydrophobic interactions with the residues of the side channel. In contrast, the tunnel is only partially occupied by the shorter pentyl chain of (-)-*trans*- Δ^9 -THC, accounting for the higher affinity of Δ^9 -THCP ($K_i = 1.2$ nM) compared to Δ^9 -THC ($K_i = 40$ nM). A different positioning of the 'tail' was instead predicted for the shorter alkyl chain homologues, Δ^9 -THCV and Δ^9 -THCB. The propyl and butyl chain of Δ^9 -THCV and Δ^9 -THCB, respectively, are too short to effectively extend within the hydrophobic channel. As stated in our previous work¹², these shorter chains accommodate within a small hydrophobic pocket delimited by Phe200, Leu359, and Met363 (Supplementary Fig. SI-7b,c). This side pocket is located at the insertion between the main hydrophobic pocket and the long channel (Fig. 3d) and seems to accommodate small hydrophobic substituents (i.e. gem-dimethyl or cycloalkyl) introduced at C1' position of the side chain of several synthetic cannabinoids, rationalizing the notable enhancement in potency and affinity for these derivatives^{35–39}.

In vivo determination of the cannabinoid profile of Δ^9 -THCP. The cannabinoid activity of Δ^9 -THCP was evaluated by the tetrad of behavioural tests on mice. The tetrad includes the assessment of spontaneous activity, immobility index (catalepsy), analgesia and changes in rectal temperature. Decrease of locomotor activity, catalepsy, analgesia and hypothermia are well-known signs of physiological manifestations of cannabinoid activity⁴⁰. After intraperitoneal (i.p.) administration, Δ^9 -THCP at 2.5 mg/kg markedly reduced the spontaneous activity of mice in the open field, while at 5 and 10 mg/kg it induced catalepsy on the ring with the immobility as compared to the vehicle treated mice (Fig. 4b,c) (0 mg/kg: 6888 cm \pm 474.8, 10 mg/kg: 166.8 cm \pm 20.50, 5 mg/kg: 127.5 cm \pm 31.32, 2.5 mg/kg: 4072 cm \pm 350.8, $p = 0.0009$). Moreover, Δ^9 -THCP administration induced a significant increase, at 10 and 5 mg/kg, in the latency for moving from the catalepsy bar (Fig. 4e) (0 mg/kg: 15.20 sec \pm 4.33, 10 mg/kg: 484.5 sec \pm 51.58, 5 mg/kg: 493.4 sec \pm 35.68, 2.5 mg/kg: 346.1 sec \pm 35.24, $p = 0.0051$). In the hot plate test (Fig. 4f), Δ^9 -THCP (10 and 5 mg/kg) induced antinociceptive effect, whereas at 2.5 mg/kg there was a trend in the induction of antinociception, which resulted not statistically significant as compared to the vehicle treated mice (0 mg/kg: 19.20 sec \pm 2.65, 10 mg/kg: 57.0 sec \pm 2.0, 5 mg/kg: 54.38 sec \pm 2.86, 2.5 mg/kg: 40.22 sec \pm 5.8, $p = 0.0044$). Δ^9 -THCP administration induced a dose dependent significant decrease, only

at 10 mg/kg, in body temperature as compared to vehicle (0 mg/kg: $0.40^{\circ}\text{C} \pm 0.25$, 10 mg/kg: $-7.10^{\circ}\text{C} \pm 0.43$, 5 mg/kg: $-5.28^{\circ}\text{C} \pm 0.36$, 2.5 mg/kg: $-4.12^{\circ}\text{C} \pm 0.38$, $p = 0.0009$) (Fig. 4d).

Semi-quantification of CBDP and Δ^9 -THCP in the FM2 extract. A semi-quantification method based on LC-HRMS allowed to provide an approximate amount of the two new phytocannabinoids in the FM2 ethanol extract. Their pentyl homologues, CBD and Δ^9 -THC, showed a concentration of 56 and 39 mg/g respectively, in accordance with the values provided by the Military Chemical Pharmaceutical Institute (59 mg/g and 42 mg/g for CBD and Δ^9 -THC respectively), obtained by the official GC-FID quantitative method. The same semi-quantitative method provided an amount of about 243 and 29 $\mu\text{g/g}$ for CBDP and Δ^9 -THCP respectively.

Discussion

Up to now, almost 150 phytocannabinoids have been detected in cannabis plant^{7,41,42}, though most of them have neither been isolated nor characterized. The well-known CBD and Δ^9 -THC have been extensively characterized and proved to possess interesting pharmacological profiles^{43–47}, thus the attention towards the biological activity of their known homologs like CBDV and Δ^9 -THCV has recently grown as evidenced by the increasing number of publications per year appearing on Scopus. Other homologs like those belonging to the orcinoid series are scarcely investigated likely due to their very low amount in the plant that makes their isolation very challenging. In recent years, the agricultural genetics research has made great progresses on the selection of rare strains that produce high amounts of CBDV, CBG and Δ^9 -THCV^{48–50}, thus it would not be surprising to see in the near future cannabis varieties rich in other minor phytocannabinoids. This genetic selection would enable the production of extracts rich in a specific phytocannabinoid with a characteristic pharmacological profile. For this reason, it is important to carry out a comprehensive chemical profiling of a medicinal cannabis variety and a thorough investigation of the pharmacological activity of minor and less known phytocannabinoids.

As the pharmacological activity of Δ^9 -THC is particularly ascribed to its affinity for CB₁ receptor, the literature suggests that the latter can be increased by elongating the alkyl side chain, which represents the main cannabinoid pharmacophoric driving force¹⁴. Therefore, taking THC as the lead compound, a series of cannabinoids have been chemically synthesized and their biological potency resulted several times higher than Δ^9 -THC itself¹⁵. To the best of our knowledge, naturally occurring cannabinoids with a linear alkyl side chain longer than five terms have never been detected or even putatively identified in cannabis plant. However, the cutting-edge technological platform of the Orbitrap mass spectrometry and the use of advanced analytical techniques like metabolomics can enable the discovery and identification of new compounds with a high degree of confidence even when present in traces in complex matrices^{42,51}. In the present work, we report for the first time the isolation and full characterization of two new CBD and Δ^9 -THC heptyl homologs, which we named cannabidiphorol (CBDP) and Δ^9 -tetrahydrocannabiphorol (Δ^9 -THCP), respectively. These common names were derived from the traditional naming of phytocannabinoids based on the resorcinyl residue, in this case corresponding to sphaerophorol.

The biological results obtained in the *in vitro* binding assay indicated an affinity for CB₁ receptor more than thirty-fold higher compared to the one reported for Δ^9 -THC in the literature¹⁴. Also, this encouraging data was supported by *in vivo* evaluation of the cannabimimetic activity by the tetrad test, where Δ^9 -THCP decreased locomotor activity and rectal temperature, induced catalepsy and produced analgesia miming the properties of full CB₁ receptor agonists (Fig. 4). In particular, Δ^9 -THCP proved to be as active as Δ^9 -THC but at lower doses. In fact, the minimum THC dose used in this kind of test is 10 mg/kg, whereas Δ^9 -THCP resulted active at 5 mg/kg in three of the four tetrad tests. These results, accompanied by the docking data, are in line with the extensive structure-activity relationship (SAR) studies performed through the years on synthetic cannabinoids, revealing the importance of the length of the alkyl chain in position 3 on the resorcinyl moiety in modulating the ligand affinity at CB₁ receptor.

Although the amount of the heptyl homologues of CBD and Δ^9 -THC in the FM2 variety could appear trifling, both *in vitro* and *in vivo* preliminary studies reported herein on Δ^9 -THCP showed a cannabimimetic activity several times higher than its pentyl homolog Δ^9 -THC. Moreover, it is reasonable to suppose that other cannabis varieties may contain even higher percentages of Δ^9 -THCP. It is also important to point out that there exists an astonishing variability of subject response to a cannabis-based therapy even with an equal Δ^9 -THC dose^{52–54}. It is therefore possible that the psychotropic effects are due to other extremely active phytocannabinoids such as Δ^9 -THCP. However, up to now nobody has ever searched for this potent phytocannabinoid in medicinal cannabis varieties. In our opinion, this compound should be included in the list of the main phytocannabinoids to be determined for a correct evaluation of the pharmacological effect of the cannabis extracts administered to patients. In fact, we believe that the discovery of an extremely potent THC-like phytocannabinoid may shed light on several pharmacological effects not ascribable solely to Δ^9 -THC.

Ongoing studies are devoted to the investigation of the pharmacological activity of CBDP and to expand that of Δ^9 -THCP. It is known that CBD binds with poor affinity to both CB₁ and CB₂ receptors⁵⁵. Therefore, the evaluation of the cannabimimetic activity of CBDP does not appear to be a high priority, although science can hold great surprises. Our current work is rather focused on testing its anti-inflammatory, anti-oxidant and anti-epileptic activity, which are typical of CBD⁴⁶.

Methods

Plant material. FM2 cannabis variety is obtained from the strain CIN-RO produced by the Council for Agricultural Research and Economics (CREA) in Rovigo (Italy) and provided to the Military Chemical Pharmaceutical Institute (MCPI, Firenze, Italy) for breeding. FM2 inflorescence (batch n. 6A32/1) was supplied by the MCPI with the authorization of the Italian Ministry of Health (prot. n. SP/062). The raw plant material (10 g) was finely grinded and divided into two batches: one batch (500 mg) was extracted with 50 mL of ethanol 96% according to the procedure indicated by the monograph of *Cannabis Flos* of the German Pharmacopoeia⁵⁶

and was analyzed by UHPLC-HESI-Orbitrap after proper dilution with acetonitrile ($\times 100$). The remaining 9.5 g were extracted following the protocol of Pellati *et al.* with some modifications²⁶. Briefly, freeze-dried plant material was extracted with 400 mL of *n*-hexane for 15 min under sonication in an ice bath. Samples were centrifuged for 10 min at $2000 \times g$ and the supernatants collected. The procedure was repeated twice more on the pellets. The combined supernatants were then dried under reduced pressure and resuspended in 10 mL of acetonitrile, filtered and used for the isolation of CBDPA and THCPA by semi-preparative liquid chromatography.

Isolation of natural CBDP and Δ^9 -THCP. Aliquots (1 mL) of the solution obtained as described in the 'Plant Material' section were injected in a semi-preparative LC system (Octave 10 Sempa Bioscience, Madison, USA). The chromatographic conditions used are reported in the paper by Citti *et al.*¹¹. The column employed was a Luna C₁₈ with a fully porous silica stationary phase (Luna 5 μ m C18(2) 100 Å, 250×10 mm) (Phenomenex, Bologna, Italy) and a mixture of acetonitrile:0.1% aqueous formic acid 70:30 (v/v) was used as mobile phase at a flow rate of 5 mL/min. CBDPA and THCPA (retention time 19.0 min and 75.5 min respectively) were isolated as reported in our previous work¹¹. The fractions containing CBDPA and THCPA were analyzed by UHPLC-HESI-Orbitrap. The fractions containing predominantly either one or the other cannabinoid were separately combined and dried on the rotavapor at 70 °C. Each residue was subject to decarboxylation at 120 °C for two hours in oven. An amount of about 0.6 mg of CBDP and about 0.3 mg of Δ^9 -THCP was obtained.

UHPLC-HESI-Orbitrap metabolomic analysis. FM2 extracts were analyzed on a Thermo Fisher Scientific Ultimate 3000 system equipped with a vacuum degasser, a binary pump, a thermostated autosampler, a thermostated column compartment and interfaced to a heated electrospray ionization source and a Q-Exactive Orbitrap mass spectrometer (UHPLC-HESI-Orbitrap). The parameters of the HESI source were set according to Citti *et al.*¹¹: capillary temperature, 320 °C; vaporizer temperature, 280 °C; electrospray voltage, 4.2 kV (positive mode) and 3.8 kV (negative mode); sheath gas, 55 arbitrary units; auxiliary gas, 30 arbitrary units; S lens RF level, 45. Analyses were acquired using the Xcalibur 3.0 software (Thermo Fisher Scientific, San Jose, CA, USA) in full scan data-dependent acquisition (FS-dd-MS²) in positive (ESI+) and negative (ESI-) mode at a resolving power of 70,000 FWHM at m/z 200. A scan range of m/z 250–400, an AGC of $3e6$, an injection time of 100 ms and an isolation window for the filtration of the precursor ions of m/z 0.7 were chosen as the optimal parameters for the mass analyzer. A normalized collision energy (NCE) of 20 was used to fragment the precursor ions. Extracted ion chromatograms (EIC) of the $[M+H]^+$ and $[M-H]^-$ molecular ions were derived from the total ion chromatogram (TIC) of the FM2 extracts and matched with pure analytical standards for accuracy of the exact mass (5 ppm), retention time and MS/MS spectrum.

The chromatographic separation was carried out on a Poroshell 120 SB-C18 (3.0×100 mm, 2.7 μ m, Agilent, Milan, Italy) following the conditions employed for our previous work¹¹.

A semi-quantitative analysis of Δ^9 -THC and CBD and their heptyl analogs CBDP and Δ^9 -THCP was achieved using a calibration curve with an external standard. A stock solution of CBD and Δ^9 -THC, CBDP and Δ^9 -THCP (1 mg/mL) was properly diluted to obtain five non-zero calibration points at the final concentrations of 50, 100, 250, 500, and 1000 ng/mL for CBD and Δ^9 -THC and of 1, 5, 10, 25, and 50 ng/mL for CBDP and Δ^9 -THCP. A standard solution of Δ^9 -THC-*d*₃ was added at each calibration standard at a final concentration of 50 ng/mL. The linearity was assessed by the coefficient of determination (R^2), which was greater than 0.993 for each analyte.

Synthetic procedure. All reagents and solvents were employed as purchased without further purification unless otherwise specified. The following abbreviations for common organic solvents have been used herein: diethyl ether (Et₂O); dichloromethane (DCM); cyclohexane (CE). Reaction monitoring was performed by thin-layer chromatography on silica gel (60F-254, E. Merck) and checked by UV light, or alkaline KMnO₄ aqueous solution^{57–59}. Reaction products were purified, when necessary, by flash chromatography on silica gel (40–63 μ m) with the solvent system indicated. NMR spectra were recorded on a Bruker 400 or Bruker 600 spectrometer working respectively at 400.134 MHz and 600.130 MHz for ¹H and at 100.62 MHz or 150.902 MHz for ¹³C. Chemical shifts (δ) are in parts per million (ppm) and they were referenced to the solvent residual peaks (CDCl₃, $\delta = 7.26$ ppm for proton and $\delta = 77.20$ ppm for carbon); coupling constants are reported in hertz (Hz); splitting patterns are expressed with the following abbreviations: singlet (s), doublet (d), triplet (t), quartet (q), double doublet (dd), quintet (qnt), multiplet (m), broad signal (b). Monodimensional spectra were acquired with a spectral width of 8278 Hz (for ¹H-NMR) and 23.9 kHz (for ¹³C-NMR), a relaxation delay of 1 s, and 32 and 1024 number of transients for ¹H-NMR and ¹³C-NMR, respectively¹². The COSY spectra were recorded as a 2048 \times 256 matrix with 2 transients per t1 increment and processed as a 2048 \times 1024 matrix; the HSQC spectra were collected as a 2048 \times 256 matrix with 4 transients per t1 increment and processed as a 2048 \times 1024 matrix, and the one-bond heteronuclear coupling value was set to 145 Hz; the HMBC spectra were collected as a 4096 \times 256 matrix with 16 transients per t1 increment and processed as a 4096 \times 1024 matrix, and the long-range coupling value was set to 8 Hz¹². Circular dichroism (CD) and UV spectra were acquired on a Jasco (Tokyo, Japan) J-1100 spectropolarimeter using a 50 nm/min scanning speed. Quartz cells with a 10 mm path length were employed to record spectra in the 500–220 nm range¹². Optical rotation (λ) was measured with a Polarimeter 241 (cell-length 100 mm, volume 1 mL) from Perkin-Elmer (Milan, Italy). The synthetic procedures described below were adjusted from previously published works^{12,57}.

Synthesis of (1'R,2'R)-4-heptyl-5'-methyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol, (-)-trans-CBDP

(1*S*,4*R*)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (146 mg, 0.96 mmol, 0.9 eq.), solubilized in 15 mL of anhydrous DCM, was added over a period of 20 min to a stirred solution of 5-heptylbenzene-1,3-diol (222 mg, 1.07 mmol, 1 eq.) and *p*-toluenesulfonic acid (20 mg, 0.11 mmol, 0.1 eq.) in anhydrous DCM (15 mL) at room temperature and under a positive pressure of argon. After stirring in the same conditions for 1 h, the reaction was

quenched with 10 mL of a saturated aqueous solution of NaHCO₃. The mixture was partitioned between Et₂O and water. The organic layer was separated and washed with brine, dried with anhydrous Na₂SO₄ and evaporated. The residue was chromatographed (ratio crude:silica 1/120, eluent: CE:DCM 8/2). All the chromatographic fractions were analyzed by HPLC-UV and UHPLC-HESI-Orbitrap and only the fractions containing exclusively CBDP were concentrated to give 76 mg of a colorless oil (23% yield, purity > 99%).

¹H NMR (400 MHz, CDCl₃) δ 6.10–6.30 (m, 2 H), 5.97 (bs, 1 H), 5.57 (s, 1 H), 4.66 (s, 1 H), 4.66 (bs, 1 H), 4.56 (s, 1 H), 3.89–3.81 (m, 1 H), 2.52–2.35 (m, 3 H), 2.24 (td, *J* = 6.1, 12.7 Hz, 1 H), 2.09 (ddt, *J* = 2.4, 5.1, 17.9 Hz, 1 H), 1.89–1.74 (m, 5 H), 1.65 (s, 3 H), 1.55 (qnt, *J* = 7.6 Hz, 2 H), 1.28 (td, *J* = 4.7, 8.2, 9.0 Hz, 8 H), 0.87 (t, *J* = 6.7 Hz, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 156.27, 154.09, 149.56, 143.23, 140.22, 124.30, 113.93, 111.01, 109.91, 108.26, 46.33, 37.46, 35.70, 31.99, 31.14, 30.59, 29.43, 29.35, 28.60, 23.86, 22.84, 20.71, 14.29. HRMS *m/z* [M + H]⁺ calcd. for C₂₃H₃₅O₂⁺: 343.2632. Found: 343.2629; [M-H]⁻ calcd. for C₂₃H₃₃O₂⁻: 341.2475. Found: 341.2482. [α]_D²⁰ = -146° (c 1.0, ACN).

Synthesis of (6*aR*,10*aR*)-3-heptyl-6,6,9-trimethyl-6*a*,7,10,10*a*-tetrahydro-6*H*-benzo[*c*]chromen-1-ol, (-)-*trans*-Δ⁸-THCP

The set-up of the reaction for the synthesis of (-)-*trans*-Δ⁸-THCP was performed as described for (-)-*trans*-CBDP and the resulting mixture was stirred at room temperature for 48 h. The mixture was diluted with Et₂O, and washed with a saturated solution of NaHCO₃ (10 mL). The organic layer was collected, washed with brine, dried (anhydrous Na₂SO₄) and concentrated. After purification over silica gel (ratio crude:silica 1/150, eluent: CE:Et₂O 95/5) 315 mg of a colorless oil (46% yield) were obtained.

¹H NMR (400 MHz, CDCl₃) δ 6.28 (d, *J* = 1.6 Hz, 1 H), 6.10 (d, *J* = 1.6 Hz, 1 H), 5.46–5.39 (m, 1 H), 4.78 (s, 1 H), 3.20 (dd, *J* = 4.5, 16.0 Hz, 1 H), 2.70 (td, *J* = 4.7, 10.8 Hz, 1 H), 2.44 (td, *J* = 2.3, 7.4 Hz, 2 H), 2.21–2.10 (m, 1 H), 1.92–1.76 (m, 3 H), 1.70 (s, 3 H), 1.63–1.52 (m, 2 H), 1.38 (s, 3 H), 1.30 (tt, *J* = 4.3, 9.4, 11.8 Hz, 8 H), 1.11 (s, 3 H), 0.88 (t, *J* = 7.0 Hz, 3 H).

Synthesis of (6*aR*,10*aR*)-3-heptyl-9-chloro-6,6,9-trimethyl-6*a*,7,8,9,10,10*a*-hexahydro-6*H*-benzo[*c*]chromen-1-ol (HCl-THCP)

1 N ZnCl₂ in Et₂O (440 μL, 0.44 mmol, 0.5 eq.) was added to a stirred solution of Δ⁸-THCP (300 mg, 0.87 mmol, 1 eq.) in 20 mL of anhydrous DCM, at room temperature and under nitrogen atmosphere. After 30 min, the reaction was cooled at 0 °C and 2 mL of 4 N HCl in dioxane was added. The resulting mixture was stirred at room temperature, overnight and then diluted with Et₂O. The organic layer was collected and washed, in sequence, with an aqueous saturated solution of NaHCO₃ and brine. After dehydration with anhydrous Na₂SO₄, the organic phase was concentrated to give 305 mg (93% yield) of a yellowish oil, pure enough to be used in the next step without further purification.

¹H NMR (400 MHz, CDCl₃) δ 6.24 (d, *J* = 1.7 Hz, 1 H), 6.07 (d, *J* = 1.6 Hz, 1 H), 4.94 (s, 1 H), 3.45 (dd, *J* = 2.9, 14.4 Hz, 1 H), 3.05 (td, *J* = 2.9, 11.3 Hz, 1 H), 2.42 (td, *J* = 1.5, 7.4 Hz, 2 H), 2.20–2.12 (m, 1 H), 1.80–1.71 (m, 1 H), 1.66 (s, 4 H), 1.60–1.51 (m, 2 H), 1.49–1.42 (m, 1 H), 1.38 (s, 3 H), 1.34–1.18 (m, 10 H), 1.13 (s, 3 H), 0.87 (t, *J* = 6.6 Hz, 3 H). ESI-MS *m/z* [M + H]⁺ calcd. for C₂₃H₃₆³⁵[Cl]O₂⁺: 379.2. Found: 379.4. Calcd. for C₂₃H₃₆³⁷[Cl]O₂⁺: 381.2. Found: 381.3.

Synthesis of (6*aR*,10*aR*)-3-heptyl-6,6,9-trimethyl-6*a*,7,8,10*a*-tetrahydro-6*H*-benzo[*c*]chromen-1-ol, (-)-*trans*-Δ⁹-THCP.

HCl-THCP (305 mg, 0.82 mmol, 1 eq.) was solubilized in 10 mL of anhydrous toluene and cooled at -15 °C. 1.75 N potassium *t*-amylate in toluene (1.17 mL, 2.05 mmol, 2.5 eq.) was added dropwise with a syringe to the first solution under a positive pressure of argon. The mixture was stirred in the same condition for 15 min and then at 60 °C for 1 h. After cooling at room temperature, the reaction was quenched with a 1% solution of ascorbic acid and diluted with Et₂O. The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and concentrated. The residue was chromatographed (ratio crude/silica 1:300, hexane:*i*-propyl ether 9/1) to give 232 mg of a greenish oil (83% yield). 50 mg of (-)-*trans*-Δ⁹-THCP were further purified by semipreparative HPLC to prepare a pure analytic standard (purity > 99.9%).

¹H NMR (600 MHz, CDCl₃) δ 6.30 (t, *J* = 2.0 Hz, 1 H), 6.27 (d, *J* = 1.6 Hz, 1 H), 6.14 (d, *J* = 1.5 Hz, 1 H), 4.75 (s, 1 H), 3.20 (dt, *J* = 2.5, 10.8 Hz, 1 H), 2.43 (dd, *J* = 6.4, 8.9 Hz, 2 H), 2.22–2.11 (m, 2 H), 1.97–1.87 (m, 1 H), 1.69–1.65 (m, 4 H), 1.58–1.50 (m, 2 H), 1.43–1.37 (m, 4 H), 1.34–1.21 (m, 8 H), 1.09 (s, 3 H), 0.87 (t, *J* = 6.6 Hz, 3 H). ¹³C NMR (151 MHz, CDCl₃) δ 154.97, 154.34, 143.02, 134.59, 123.92, 110.30, 109.22, 107.72, 77.38, 46.01, 35.72, 33.78, 31.99, 31.37, 31.16, 29.50, 29.38, 27.77, 25.22, 23.55, 22.87, 19.47, 14.29. HRMS *m/z* [M + H]⁺ calcd. for C₂₃H₃₅O₂⁺: 343.2632. Found: 343.2633; [M-H]⁻ calcd. for C₂₃H₃₃O₂⁻: 341.2475. Found: 341.2481. [α]_D²⁰ = -166° (c 1.0, ACN).

Binding at CB₁ and CB₂ Receptors. The binding affinity of (-)-*trans*-Δ⁹-THCP against human CB₁ and CB₂ receptors was assessed by Eurofins Discovery using a radioligand binding assay. Ten concentrations of the phytocannabinoid from 1 nM to 30 μM were tested in duplicate. [³H]CP55940 (at 2 nM, *K_d* = 2.4 nM) and [³H]WIN 55212-2 (at 0.8 nM, *K_d* = 1.5 nM) were used as specific radioligand for hCB₁ and hCB₂, respectively^{60,61}. Equation 1 was employed to calculate the percent inhibition (%*in*) of control specific binding obtained in the presence of the tested compounds.

$$\%in = 100 - \left(\frac{\text{measured specific binding}}{\text{control specific binding}} * 100 \right) \quad (1)$$

A non-linear regression analysis of the competition curves generated with mean replicate values (Eq. 2) was used to calculate the IC₅₀ values (concentration causing a half-maximal inhibition of control specific binding)⁶².

$$Y = D + \left[\frac{A - D}{1 + \left(\frac{C}{C_{50}} \right)^{nH}} \right] \quad (2)$$

Where Y is the specific binding, A is the left asymptote of the curve, D is the right asymptote of the curve, C is the compound concentration, C_{50} is the IC_{50} value and nH is the slope factor. This analysis was carried out using a software developed at Cerep (Hill software) and validated by comparing the data with that generated by the commercial software SigmaPlot 4.0 for Windows (1997 by SPSS Inc.). The inhibition constants (K_i) were determined using the Cheng Prusoff equation (Eq. 3):

$$K_i = \frac{IC_{50}}{\left(1 + \frac{L}{K_D} \right)} \quad (3)$$

where L is the concentration of the radioligand, and K_D is the affinity of the radioligand for the receptor.

The data obtained for CP 55940 (CB_1 IC_{50} = 1.7 nM, CB_1 K_i = 0.93 nM) and WIN 55212-2 (CB_2 IC_{50} = 2.7 nM, CB_2 K_i = 1.7 nM) were in accordance with the values reported in literature^{60,61}.

Docking simulation. The prediction of the binding mode of Δ^9 -THCP in complex with human CB_1 receptor was performed using Maestro 10.3 of the Schrödinger Suite⁶³. The crystallographic structure of the active conformation of CB_1 in complex with AM11542 (PDB ID: 5XRA) was downloaded from the Protein Data Bank and was used as reference for docking calculation. The protein was prepared using the Protein Preparation Wizard module⁶⁴. The chemical structure of (-)-*trans*- Δ^9 -THCP was sketched with ChemDraw 12.0 and converted from 2D to 3D with the LigPrep utility⁶⁵. Five conformations per ligand were initially generated, and appropriate ionization state and tautomers were evaluated for each conformation at physiological pH^{66,67}. Afterwards, ligand conformations were minimized with the OPLS_2005 force field. Rigid docking was performed in extra precision mode with Glide version 6.8⁶⁸.

Tetrad test. Male C57BL/6J mice (7 weeks old; $n = 5$) were treated with Δ^9 -THCP (10, 5 and 2.5 mg/kg) or vehicle (1:1:18; ethanol:Kolliphor EL:0.9% saline) by i.p. administration. Mice were evaluated for hypomotility (open field test), hypothermia (body temperature), antinociceptive (hot plate test), and cataleptic (bar test) effects, using the procedures of the tetrad tests as reported by Metna-Laurent *et al.*⁶⁹. The same animals were used in all four behavioral tests. Statistical analysis was performed using the Kruskal-Wallis test and Dunn's post hoc tests.

Body temperature. The mouse was immobilized and the probe gently inserted for 1 cm into the rectum until stabilization of temperature. Between each mouse the probe was cleaned with 70% ethanol and dried with paper towel.

Open field. The open field test was used for the evaluation of motor activity. Behavioral assays were performed 30 min after drug (or vehicle) injection. The apparatus was cleaned before each behavioral session by a 70% ethanol solution. Naïve mice were randomly assigned to a treatment group. Behaviors were recorded, stored, and analyzed using an automated behavioral tracking system (Smart v3.0, Panlab Harvard Apparatus). Mice were placed in an OFT arena (1 × w × h: 44 cm × 44 cm × 30 cm), and ambulatory activity (total distance travelled in centimeter) was recorded for 15 min and analyzed.

Bar test. The bar test was used for the evaluation of catalepsy. The bar was a 40 cm in length and 0.4 cm in diameter glass rod, which was horizontally elevated by 5 cm above the surface. Both forelimbs of the mouse were positioned on the bar and its hind legs on the floor of the cage, ensuring that the mouse was not lying down on the floor. The chronometer was stopped when the mouse descended from the bar (i.e., when the two forepaws touched the floor) or when 10 min had elapsed (i.e., cut-off time). Catalepsy was measured as the time duration each mouse held the elevated bar by both its forelimbs (latency for moving in seconds).

Hot plate. The hot plate test was performed to assess changes in the nociception. On the day of the experiment each mouse was placed on a hot plate (Ugo Basile) that was kept at a constant temperature of 52 °C. Licking of the hind paws or jumping were considered as a nociceptive response (NR) and the latency was measured in seconds 85 minutes after drug or vehicle administration, taking a cut-off time of 30 or 60 s in order to prevent tissue damage.

Animals. Male C57BL/6 mice (Charles River, Italy) of 18–20 g weight were used for the tetrad experiments. A 12 h light/dark cycle with light on at 6:00 A.M., a constant temperature of 20–22 °C, and a 55–60% humidity were maintained for at least 1 week before beginning the experiments. Mice were housed three per cage with chow and tap water available *ad libitum*. The experimental procedures employed for the work presented herein were approved by the Animal Ethics Committee of the University of Campania “L. Vanvitelli”, Naples. Animal care and welfare were entrusted to adequately trained personnel in compliance with Italian (D.L. 116/92) and European Commission (O.J. of E.C. L358/1, 18/12/86) regulations on the protection of animals used for research purposes. All efforts were made to minimize animal numbers and avoid unnecessary suffering during the experiments.

Received: 5 November 2019; Accepted: 29 November 2019;

Published online: 30 December 2019

References

- Novack, G. D. Cannabinoids for treatment of glaucoma. *Curr. Opin. Ophthalmol.* **27**, 146–150 (2016).
- Russo, E. B. Cannabis and epilepsy: an ancient treatment returns to the fore. *Epilepsy Behav.* **70**, 292–297 (2017).
- Zeremski, T., Kiprovski, B., Sikora, V., Miladinović, J. & Tubić, S. In *III International Congress, "Food Technology, Quality and Safety", 25–27 October 2016, Novi Sad, Serbia. Proceedings* 10–15 (University of Novi Sad, Institute of Food Technology).
- Mutje, P., Lopez, A., Vallejos, M., Lopez, J. & Vilaseca, F. Full exploitation of Cannabis sativa as reinforcement/filler of thermoplastic composite materials. *Composites Part A: Applied Science and Manufacturing* **38**, 369–377 (2007).
- Westerhuis, W. *Hemp for textiles: plant size matters*, Wageningen University, (2016).
- Center for Behavioral Health Statistics and Quality. 2015 National Survey on Drug Use and Health: Detailed Tables (Rockville, MD, 2016).
- Hanuš, L. O., Meyer, S. M., Muñoz, E., Tagliatala-Scafati, O. & Appendino, G. Phytocannabinoids: a unified critical inventory. *Nat. Prod. Rep.* **33**, 1357–1392, <https://doi.org/10.1039/C6NP00074F> (2016).
- Schultz, O.-E. & Haffner, G. Zur Frage der Biosynthese der Cannabinole. *Arch. Pharm.* **293**, 1–8, <https://doi.org/10.1002/ardp.19602930102> (1960).
- Niesink, R. J. M. & van Laar, M. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? *Frontiers in Psychiatry*, **4**, <https://doi.org/10.3389/fpsy.2013.00130> (2013).
- Kajima, M. & Piraux, M. The biogenesis of cannabinoids in Cannabis sativa. *Phytochemistry* **21**, 67–69, [https://doi.org/10.1016/0031-9422\(82\)80016-2](https://doi.org/10.1016/0031-9422(82)80016-2) (1982).
- Citti, C. *et al.* Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog. *J. Pharm. Biomed. Anal.* **175**, 112752, <https://doi.org/10.1016/j.jpba.2019.06.049> (2019).
- Linciano, P. *et al.* Isolation of a high affinity cannabinoid for human CB1 receptor from a medicinal cannabis variety: D9-Tetrahydrocannabutol, the butyl homologue of D9-tetrahydrocannabinol. *J. Nat. Prod.* in press, <https://doi.org/10.1021/acs.jnatprod.9b00876> (2019).
- Robertson, L. W., Lyle, M. A. & Billets, S. Biotransformation of cannabinoids by *Syncephalastrum racemosum*. *Biomed. Mass Spectrom* **2**, 266–271, <https://doi.org/10.1002/bms.1200020505> (1975).
- Bow, E. W. & Rimoldi, J. M. The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. *Perspect. Medicin. Chem.* **8**, PMC.S32171, <https://doi.org/10.4137/pmc.s32171> (2016).
- Martin, B. R. *et al.* Manipulation of the Tetrahydrocannabinol Side Chain Delineates Agonists, Partial Agonists, and Antagonists. *J. Pharmacol. Exp. Ther.* **290**, 1065–1079 (1999).
- Adams, R., Loewe, S., Jelinek, C. & Wolff, H. Tetrahydrocannabinol Homologs with Marijuana Activity. IX. *J. Am. Chem. Soc.* **63**, 1971–1973, <https://doi.org/10.1021/ja01852a052> (1941).
- Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D. & Mattison, P. G. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. *J. Neurol. Neurosurg. Psychiatry* **83**, 1125–1132, <https://doi.org/10.1136/jnnp-2012-302468> (2012).
- Pretzsch, C. M. *et al.* Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. *Neuropsychopharmacology*, **1** (2019).
- Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex[®], a Cannabis-Based Medicine. *Chem. Biodivers.* **4**, 1729–1743, <https://doi.org/10.1002/cbdv.200790150> (2007).
- Whiting, P. F. *et al.* Cannabinoids for Medical Use: A Systematic Review and Meta-analysis of Cannabinoids for Medical Use. *JAMA* **313**, 2456–2473, <https://doi.org/10.1001/jama.2015.6358> (2015).
- Garcia, A. N. & Salloum, I. M. Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: A focused review. *Am. J. Addict.* **24**, 590–598, <https://doi.org/10.1111/ajad.12291> (2015).
- Black, N. *et al.* Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *The Lancet Psychiatry*, [https://doi.org/10.1016/S2215-0366\(19\)30401-8](https://doi.org/10.1016/S2215-0366(19)30401-8) (2019).
- Finnerup, N. B. *et al.* Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol.* **14**, 162–173, [https://doi.org/10.1016/s1474-4422\(14\)70251-0](https://doi.org/10.1016/s1474-4422(14)70251-0) (2015).
- Citti, C. *et al.* Chemical and spectroscopic characterization data of ‘cannabidibutol’, a novel cannabidiol butyl analog. *Data in Brief* **26**, 104463, <https://doi.org/10.1016/j.dib.2019.104463> (2019).
- Citti, C. *et al.* A Metabolomic Approach Applied to a Liquid Chromatography Coupled to High-Resolution Tandem Mass Spectrometry Method (HPLC-ESI-HRMS/MS): Towards the Comprehensive Evaluation of the Chemical Composition of Cannabis Medicinal Extracts. *Phytochemical Analysis* **29**, 144–155, <https://doi.org/10.1002/pca.2722> (2018).
- Pellati, F. *et al.* New Methods for the Comprehensive Analysis of Bioactive Compounds in Cannabis sativa L. (hemp). *Molecules*, **23**, <https://doi.org/10.3390/molecules23102639> (2018).
- Koch, O. G., Marcus, R., Looft, Jan, Voessing, Tobias. Preparation of mixtures of cannabinoid compounds useful for therapeutic treatment. Germany patent (2015).
- Kupper, R. J. Cannabinoid active pharmaceutical ingredient for improved dosage forms. (2006).
- Nikas, S., Thakur, G. & Makriyannis, A. Synthesis of side chain specifically deuterated (–)- Δ^9 -tetrahydrocannabinols. *Journal of Labelled Compounds and Radiopharmaceuticals* **45**, 1065–1076, <https://doi.org/10.1002/jlcr.626> (2002).
- Choi, Y. H. *et al.* NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. *Phytochem Anal* **15**, 345–354, <https://doi.org/10.1002/pca.787> (2004).
- Mechoulam, R., Braun, P. & Gaoni, Y. Syntheses of Δ^9 -tetrahydrocannabinol and related cannabinoids. *J. Am. Chem. Soc.* **94**, 6159–6165, <https://doi.org/10.1021/ja00772a038> (1972).
- Jung, S. W., Cho, A. E. & Yu, W. Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations. *Sci. Rep.* **8**, 13787–13787, <https://doi.org/10.1038/s41598-018-31749-z> (2018).
- Hua, T. *et al.* Crystal structures of agonist-bound human cannabinoid receptor CB1. *Nature* **547**, 468–471, <https://doi.org/10.1038/nature23272> (2017).
- Shao, Z. *et al.* High-resolution crystal structure of the human CB1 cannabinoid receptor. *Nature* **540**, 602–606, <https://doi.org/10.1038/nature20613> (2016).
- Nikas, S. P. *et al.* Novel 1',1'-Chain Substituted Hexahydrocannabinols: 9 β -Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist. *J. Med. Chem.* **53**, 6996–7010, <https://doi.org/10.1021/jm100641g> (2010).
- Papahatjis, D. P. *et al.* Pharmacophoric Requirements for the Cannabinoid Side Chain. Probing the Cannabinoid Receptor Subsite at CB1. *J. Med. Chem.* **46**, 3221–3229, <https://doi.org/10.1021/jm020558c> (2003).
- Huffman, J. W. *et al.* Structure–activity relationships for 1',1'-dimethylalkyl- Δ^8 -tetrahydrocannabinols. *Bioorg. Med. Chem.* **11**, 1397–1410, [https://doi.org/10.1016/S0968-0896\(02\)00649-1](https://doi.org/10.1016/S0968-0896(02)00649-1) (2003).
- Nikas, S. P. *et al.* The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model. *AAPS J.* **6**, e30–e30, <https://doi.org/10.1208/aapsj060430> (2004).
- Papahatjis, D. P., Nikas, S. P., Andreou, T. & Makriyannis, A. Novel 1',1'-chain substituted Δ^8 -tetrahydrocannabinols. *Bioorg. Med. Chem. Lett.* **12**, 3583–3586, [https://doi.org/10.1016/S0960-894X\(02\)00785-0](https://doi.org/10.1016/S0960-894X(02)00785-0) (2002).
- Varvel, S. A. *et al.* Δ^9 -tetrahydrocannabinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. *J. Pharmacol. Exp. Ther.* **314**, 329–337 (2005).

41. Citti, C. *et al.* Cannabinoid Profiling of Hemp Seed Oil by Liquid Chromatography Coupled to High-Resolution Mass Spectrometry. *Frontiers in Plant Science*, **10**, <https://doi.org/10.3389/fpls.2019.00120> (2019).
42. Pavlovic, R. *et al.* Phytochemical and Ecological Analysis of Two Varieties of Hemp (*Cannabis sativa* L.) Grown in a Mountain Environment of Italian Alps. *Frontiers in Plant Science*, **10**, <https://doi.org/10.3389/fpls.2019.01265> (2019).
43. Citti, C., Pacchetti, B., Vandelli, M. A., Forni, F. & Cannazza, G. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). *J. Pharm. Biomed. Anal.* **149**, 532–540, <https://doi.org/10.1016/j.jpba.2017.11.044> (2018).
44. Citti, C. *et al.* Untargeted rat brain metabolomics after oral administration of a single high dose of cannabidiol. *J. Pharm. Biomed. Anal.* **161**, 1–11, <https://doi.org/10.1016/j.jpba.2018.08.021> (2018).
45. Palazzoli, F. *et al.* Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC–MS/MS) method for the determination of cannabidiol (CBD), Δ^9 -tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. *J. Pharm. Biomed. Anal.* **150**, 25–32, <https://doi.org/10.1016/j.jpba.2017.11.054> (2018).
46. Russo, E. B. C. Claims and Misconceptions. *Trends Pharmacol. Sci.* **38**, 198–201, <https://doi.org/10.1016/j.tips.2016.12.004> (2017).
47. Carlini, E. The good and the bad effects of (–) trans- Δ^9 -tetrahydrocannabinol (Δ^9 -THC) on humans. *Toxicol.* **44**, 461–467 (2004).
48. Brierley, D. I., Samuels, J., Duncan, M., Whalley, B. J. & Williams, C. M. A cannabigerol-rich *Cannabis sativa* extract, devoid of [INCREMENT] Δ^9 -tetrahydrocannabinol, elicits hyperphagia in rats. *Behav. Pharmacol.* **28**, 280–284, <https://doi.org/10.1097/fbp.0000000000000285> (2017).
49. Hill, T. D. M. *et al.* Cannabidiol-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. *Br. J. Pharmacol.* **170**, 679–692, <https://doi.org/10.1111/bph.12321> (2013).
50. de Meijer, E. P. M. & Hammond, K. M. The inheritance of chemical phenotype in *Cannabis sativa* L. (V): regulation of the propyl-/pentyl cannabinoid ratio, completion of a genetic model. *Euphytica* **210**, 291–307, <https://doi.org/10.1007/s10681-016-1721-3> (2016).
51. Citti, C., Braghieri, D., Vandelli, M. A. & Cannazza, G. Pharmaceutical and biomedical analysis of cannabinoids: A critical review. *J. Pharm. Biomed. Anal.* **147**, 565–579, <https://doi.org/10.1016/j.jpba.2017.06.003> (2018).
52. Wardle, M. C., Marcus, B. A. & de Wit, H. A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Δ^9 -Tetrahydrocannabinol Using a Within-Subjects Randomized Trial. *PLoS ONE* **10**, e0140501, <https://doi.org/10.1371/journal.pone.0140501> (2015).
53. Wachtel, S. R., ElSohly, M. A., Ross, S. A., Ambre, J. & de Wit, H. Comparison of the subjective effects of Δ^9 -tetrahydrocannabinol and marijuana in humans. *Psychopharmacology (Berl.)* **161**, 331–339, <https://doi.org/10.1007/s00213-002-1033-2> (2002).
54. Bedi, G., Cooper, Z. D. & Haney, M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. *Addict. Biol.* **18**, 872–881, <https://doi.org/10.1111/j.1369-1600.2011.00427.x> (2013).
55. Pertwee, R. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ^9 -tetrahydrocannabinol, cannabidiol and Δ^9 -tetrahydrocannabivarin. *Br. J. Pharmacol.* **153**, 199–215 (2008).
56. Bundesinstitut für Arzneimittel und Medizinprodukte. Cannabis Flos. *New text of the German Pharmacopoeia* (2018).
57. Linciano, P. *et al.* Aryl thiosemicarbazones for the treatment of trypanosomatid infections. *Eur. J. Med. Chem.* **146**, 423–434, <https://doi.org/10.1016/j.ejmech.2018.01.043> (2018).
58. Christodoulou, M. S. *et al.* Probing an Allosteric Pocket of CDK2 with Small Molecules. *ChemMedChem* **12**, 33–41, <https://doi.org/10.1002/cmdc.201600474> (2017).
59. Pulis, A. P. *et al.* Asymmetric Synthesis of Tertiary Alcohols and Thiols via Nonstabilized Tertiary α -Oxy- and α -Thio-Substituted Organolithium Species. *Angewandte Chemie International Edition* **56**, 10835–10839, <https://doi.org/10.1002/anie.201706722> (2017).
60. Rinaldi-Carmona, M. *et al.* Characterization of two cloned human CB1 cannabinoid receptor isoforms. *J. Pharmacol. Exp. Ther.* **278**, 871–878 (1996).
61. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**, 61–65, <https://doi.org/10.1038/365061a0> (1993).
62. Ponzoni, L. *et al.* The tyrosine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors. *Psychopharmacology (Berl.)* **231**, 4681–4693, <https://doi.org/10.1007/s00213-014-3619-x> (2014).
63. Schrodinger Release 2014-3: Maestro, Schrodinger LLC (New York, NY (USA), 2014).
64. Schrödinger Suite 2014-3: Protein Preparation Wizard; Epik, Schrödinger, LLC (New York, NY (USA), 2014).
65. Schrodinger Release 2014-3: LigPrep, Schrodinger LLC (New York, NY (USA), 2014).
66. Citti, C. *et al.* 7-Chloro-5-(furan-3-yl)-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-Dioxide as Positive Allosteric Modulator of α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor. The End of the Unsaturated-Inactive Paradigm? *ACS Chem. Neurosci.* **7**, 149–160, <https://doi.org/10.1021/acschemneuro.5b00257> (2016).
67. Battisti, U. M. *et al.* 5-Arylbenzothiadiazine Type Compounds as Positive Allosteric Modulators of AMPA/Kainate Receptors. *ACS Med. Chem. Lett.* **3**, 25–29, <https://doi.org/10.1021/ml200184w> (2012).
68. Schrodinger Release 2014-3: Glide (Version6.8), Schrodinger LLC (New York, NY (USA), 2014).
69. Metna-Laurent, M., Mondésir, M., Grel, A., Vallée, M. & Piazza, P. V. Cannabinoid-Induced Tetrad in Mice. *Curr. Protoc. Neurosci.* **80**, 9.59. 51–59.59. 10 (2017).

Acknowledgements

This work was supported by UNIHEMP research project “Use of industrial hemp biomass for energy and new biochemicals production” (ARS01_00668) funded by Fondo Europeo di Sviluppo Regionale (FESR) (within the PON R&I 2017–2020 – Axis 2 – Action II – OS 1.b). Grant decree UNIHEMP prot. n. 2016 of 27/07/2018; CUP B76C18000520005. We are also thankful to the Military Chemical Pharmaceutical Institute of Florence for providing the FM2 cannabis inflorescence.

Author contributions

G.C. developed and supervised the project, C.C. and P.L. conceived the experiments plan and drafted the manuscript, C.C. and F.R. carried out the UHPLC-HRMS analyses, P.L. performed the stereoselective syntheses and characterization, P.L. and G.G. performed the docking simulations, L.L., M.I. and S.M. performed the *in vivo* tetrad tests, A.L. and A.L.C. developed the semi-quantification method, F.F. and M.A.V. analyzed the binding assay data. All authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-019-56785-1>.

Correspondence and requests for materials should be addressed to G.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com